Interim report January

Interim report January - June 2011


  · Net sales for the first six months were SEK 44.9 million (41.5), an
increase of 8.2%.
  · Net sales for the second quarter were SEK 24.4 million (21.2), an
increase of 14.8%.
  · Currency effects had a negative impact of SEK 4.7 million on sales
for the first six months and a negative impact on sales of SEK 2.4
million in the second quarter.
  · Sales in local currencies for the first six months were up 8% in
Europe and 20% in North America year on year. In the second quarter,
sales were up by 5% in Europe and 18% in North America.
  · Operating loss (EBIT) for the first six months was SEK 11.9 million
(+3.9), with an operating loss of SEK 8.7 million (-0.7) for the second
quarter. Non-recurring costs of about SEK 7 million impacted results for
the first six months, of which SEK 4.5 million were charged to the
second quarter.
  · Loss after tax for the first six months was SEK 373.6 million
(-0.1). The results were impacted with impairment of the value of the
associated companies of SEK 358 million, of which SEK118 million was
charged to the second quarter. The impairment includes IMED which did
not reach its required targets and were fully written down.
  · Loss per share for the first six months basic and diluted was SEK
21.62 (+0.08), with a loss per share of SEK -7.37 (-0.07) for the second
quarter.
  · Equity per share was SEK 11.65 (34.19).
  · The equity/assets ratio was 41 percent (68).

Key events during the second quarter

  · Allenex divested its holdings in the associated company OrtoWay AB.
  · In June, shareholders at the Annual General Meeting decided to
change the company's name from LinkMed AB (publ) to Allenex AB (publ).
  · In May, Allenex acquired NorDiag ASA's holdings in Olerup
International AB, now controlling 75 percent of both Olerup
International AB and Olerup GmbH.
  · In May, Anders Karlsson was appointed as new CEO of the company.
  · Olerup SSP entered into an exclusive five-year agreement covering
the global marketing and distribution rights for SBT technology for HLA
typing and sequence analysis software.

Key events after the period end

  · In July, Olle Olerup left his position as CEO of the Allenex
subsidiary Olerup SSP AB.
  · On August 9 the board of directors called an extraordinary general
meeting of shareholders, which will be held in Stockholm on September 7.
  · In August, it was finalized that Allenex will divest its ownership
stake in NovaHep AB and
Recopharma AB to Alden Impact Capital AG.

CEO Anders karlsson's comments on the second quarter 2011:
“The increase in sales is very encouraging and in line with
expectations. We continue to win market share above all in North America
and with new products in our portfolio I am hopeful for continued
revenue growth in the next quarters. The change of company name to
Allenex clearly marks that we are now a transplantation sector company
focused on facilitating successful transplants for more patient. This
year is a period where we fully change the strategy of our business.
This means that the year is burdened with costs associated with the
strategy change. In the current market conditions, difficulties in
finding new owners for our associated companies, as well as negative
developments for some of them, mean that we have again written down the
value of these holdings.”

Allenex AB discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 13:00 (CET) on August 25,
2011.

For more information please contact:
Anders Karlsson, CEO Allenex, AB tel: +46 70-918 0010, email:
anders.karlsson@allenex.se
Okee Williams, tel: +46 70-60 053 64, email: okee.williams@allenex.se

Or visit www.allenex.com
Interim report January - June 2011

Attachments
